Foiu@i@attempts to restore weight loss in psychiatric patients have included hyperalimentation (Weir Mitchell, 8) and sub-coma insulin therapy (Debenham et a!., 2 ; Sargant and Craske, 5 ; Sullivan, 7) . The aim of the present trial was to compare weight gains in a group of patients given repeated small doses of in sulin with two other groups to whom oral hypoglycaemic agents were admiis tered, and with a control group. The drugs used were tolbutamide and chior daily dosage, but tolbutamide, being a shorter acting drug, was given in divided doses to maintain depression of blood sugar over the 24 hours. The subjects were in-patients in a general hospital psychiatric unit who had suffered weight loss prior to admission. As the average length of stay in this unit is four weeks, patients could not serve as their own controls. The trial comprised 42 patients, 31 women and 11 men, with an age range of 23 to 68 years. Patients were allocated to the four groups at random. No selection on clinical grounds was made except that patients suffering from serious physical disease were excluded. Weighing took place at the start of the trial and thereafter twice weekly, patients being weighed in the same night attire on each occasion. 
diabetes meffitus, and known to induce hypoglycaemia in non-diabetic subjects (Hoenig and Gittleson, 4; Cardonnet et a!., 1; Garcia Reyes et a!., 3). Pharma cologically there are no qualititative differences in their mode ofaction. Stowers et a!., (6) found the half-life of tolbutamide to be 3 â€˜¿ 5 hours and that of chlor propamide 34 â€˜¿ 5 hours. The prolonged action of chiorpropamide permits once daily dosage, but tolbutamide, being a shorter acting drug, was given in divided doses to maintain depression of blood sugar over the 24 hours. The subjects were in-patients in a general hospital psychiatric unit who had suffered weight loss prior to admission. As the average length of stay in this unit is four weeks, patients could not serve as their own controls. The trial comprised 42 patients, 31 women and 11 men, with an age range of 23 to 68 years. Patients were allocated to the four groups at random. No selection on clinical grounds was made except that patients suffering from serious physical disease were excluded. Weighing took place at the start of the trial and thereafter twice weekly, patients being weighed in the same night attire on each occasion. There were no significant differences between the groups.
RESULTS
The hypoglycaemic medication produced no side-effects. Table I Thus the 3 male insulin patients, but not the 8 female insulin patients, had significantly higher weight gains than the tolbutamide, chiorpropamide and control groups. Gains in the other groups did not differ significantly. In both the male and female sample weight gains of the control group were the smallest.
Age had no significant effect on results. Correlation co-efficients between initial weights and mean weight gains did not reach significant levels. For the purpose of assessing psychiatric outcome, patients were rated as follows: â€oe¿ excellentâ€•, â€oe¿ goodâ€•, â€oe¿ fairâ€• and â€oe¿ poorâ€•. Mean daily weight gains in respect to outcome are shown on Table II . Abbreviations are as in Table I . Highest weight gains obtained in patients rated â€oe¿ excellentâ€•, and least gains in those rated â€oe¿ poorâ€•. In the â€oe¿ goodâ€• and â€oe¿ fairâ€• categories the weight gains did not correlate with psychiatric improvement.
CONCLUSION
Though numbers are small, it emerges that the two oral hypoglycaemic drugs in the dosage used in this trial were no more effective than insulin in producing weight gains. Only the male insulin group showed significantly higher weight gains than the controls.
